应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CPRX Catalyst Pharmaceutical Partners
盘前交易 07-22 08:31:09 EDT
16.94
+0.22
+1.32%
盘前
16.94
+0.00
0.00%
08:21 EDT
最高
17.02
最低
16.69
成交量
52.73万
今开
16.80
昨收
16.72
日振幅
1.97%
总市值
20.01亿
流通市值
17.22亿
总股本
1.18亿
成交额
892.12万
换手率
0.52%
流通股本
1.02亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨5.05%
自选股智能写手 · 07-11
Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨5.05%
Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻
Reuters · 06-14
Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻
Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻
Reuters · 06-07
Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻
Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻
Reuters · 05-28
Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻
Catalyst Pharmaceuticals, Inc.2024财年第一财季实现净利润23.28百万美元,同比减少21.27%
自选股智能写手 · 05-18
Catalyst Pharmaceuticals, Inc.2024财年第一财季实现净利润23.28百万美元,同比减少21.27%
HC Wainwright & Co.:维持Catalyst Pharmaceuticals(CPRX.US)评级,由买入调整至买入评级, 目标价由24.00美元调整至26.00美元。
智通财经 · 05-10
HC Wainwright & Co.:维持Catalyst Pharmaceuticals(CPRX.US)评级,由买入调整至买入评级, 目标价由24.00美元调整至26.00美元。
Catalyst Pharmaceuticals Inc 预计每股收益 17 美分 - 财报前瞻
Reuters · 05-07
Catalyst Pharmaceuticals Inc 预计每股收益 17 美分 - 财报前瞻
Catalyst Pharmaceuticals, Inc.盘中异动 大幅拉升5.02%
自选股智能写手 · 03-28
Catalyst Pharmaceuticals, Inc.盘中异动 大幅拉升5.02%
Catalyst Pharmaceuticals, Inc.2023财年实现净利润71.41百万美元,同比减少14.05%
自选股智能写手 · 03-04
Catalyst Pharmaceuticals, Inc.2023财年实现净利润71.41百万美元,同比减少14.05%
Catalyst Pharmaceuticals, Inc.股价拉升11.61% 市值涨2.25亿美元
自选股智能写手 · 02-29
Catalyst Pharmaceuticals, Inc.股价拉升11.61% 市值涨2.25亿美元
嗡嗡声--美国股票走势-Voyager Therapeutics、GoodRx Holdings、Tenet Healthcare
Reuters · 02-29
嗡嗡声--美国股票走势-Voyager Therapeutics、GoodRx Holdings、Tenet Healthcare
BUZZ-催化剂公司第四季度收入增长
Reuters · 02-29
BUZZ-催化剂公司第四季度收入增长
Catalyst Pharmaceuticals Inc 预计每股收益 27 美分 - 财报前瞻
Reuters · 02-27
Catalyst Pharmaceuticals Inc 预计每股收益 27 美分 - 财报前瞻
加载更多
公司概况
公司名称:
Catalyst Pharmaceutical Partners
所属市场:
NASDAQ
上市日期:
--
主营业务:
Catalyst Pharmaceuticals, Inc.于2006年7月在特拉华州注册成立。该公司是一家商业阶段、以患者为中心的生物制药公司,专注于为患有罕见和难以治疗的疾病的患者提供新的高质量药物的许可、开发和商业化。该公司利用协调一致的勤奋努力,寻找能够改善那些患有罕见或难以治疗的疾病的人的生活的疗法。
发行价格:
--
{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceutical Partners","latestPrice":16.94,"timestamp":1721419200000,"preClose":16.72,"halted":0,"volume":527321,"hourTrading":{"tag":"盘前","latestPrice":16.94,"preClose":16.94,"latestTime":"08:21 EDT","volume":189,"amount":3182.7503610000003,"timestamp":1721650889709},"delay":0,"floatShares":101655423,"shares":118115079,"eps":0.563915,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.22,"latestTime":"07-22 08:31:09 EDT","open":16.8,"high":17.02,"low":16.6901,"amount":8921249.371902,"amplitude":0.019731,"askPrice":17.3,"askSize":320,"bidPrice":15.5,"bidSize":101,"shortable":3,"etf":0,"ttmEps":0.563915,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721655000000},"adr":0,"listingDate":1162962000000,"adjPreClose":16.94,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":16.94,"preClose":16.94,"latestTime":"08:21 EDT","volume":189,"amount":3182.7503610000003,"timestamp":1721650889709},"postHourTrading":{"tag":"盘后","latestPrice":16.94,"preClose":16.94,"latestTime":"19:42 EDT","volume":16923,"amount":286660.81,"timestamp":1721432555787},"volumeRatio":0.6320288250677173,"impliedVol":0.3359,"impliedVolPercentile":0.168},"requestUrl":"/m/hq/s/CPRX","defaultTab":"news","newsList":[{"id":"2450367051","title":"Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450367051","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450367051?lang=zh_cn&edition=full","pubTime":"2024-07-11 23:33","pubTimestamp":1720711999,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日23时33分,Catalyst Pharmaceuticals, Inc.股票出现波动,股价急速上涨5.05%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.59%。Catalyst Pharmaceuticals, Inc.公司简介:Catalyst Pharmaceuticals Inc是一家生物制药公司。消息层面,截至23时33分,《美银证券维持Catalyst Pharmaceuticals买入评级》资讯为影响Catalyst Pharmaceuticals, Inc.的重要信息。该信息摘要如下:美银证券分析师Jason Gerberry维持$Catalyst Pharmaceuticals $买入评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112333199681c0ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112333199681c0ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CPRX"],"gpt_icon":0},{"id":"2443278296","title":"Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2443278296","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443278296?lang=zh_cn&edition=full","pubTime":"2024-06-14 21:02","pubTimestamp":1718370139,"startTime":"0","endTime":"0","summary":" * Catalyst Pharmaceuticals Inc 将于6月17日公布截至2024年6月30日的季度业绩(估计),预计该公司的季度收入将出现增长。) * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元,高于其上次收盘价 15.33 美元。6月14日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2441068672","title":"Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2441068672","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441068672?lang=zh_cn&edition=full","pubTime":"2024-06-07 20:35","pubTimestamp":1717763712,"startTime":"0","endTime":"0","summary":" * Catalyst Pharmaceuticals Inc 预计将在 6 月 10 日公布的截至 0001 年 1 月 1 日的业绩报告(估计) 中显示出季度收入的增长。) * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元,高于其上次收盘价 15.76 美元。6月7日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2438371324","title":"Catalyst Pharmaceuticals Inc 预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2438371324","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438371324?lang=zh_cn&edition=full","pubTime":"2024-05-28 21:01","pubTimestamp":1716901273,"startTime":"0","endTime":"0","summary":" * Catalyst Pharmaceuticals Inc 预计在5月30日公布的截至2024年6月30日的业绩报告中将显示季度收入增长(预计) * 根据7位分析师基于LSEG数据的平均估计,这家总部位于佛罗里达州科勒尔盖布尔斯的公司的营收预计将从去年同期的9958万美元增长12.4%,达到1.1196亿美元。) * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元,高于其上次收盘价 15.87 美元。5月28日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2436154945","title":"Catalyst Pharmaceuticals, Inc.2024财年第一财季实现净利润23.28百万美元,同比减少21.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436154945","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436154945?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:15","pubTimestamp":1715962545,"startTime":"0","endTime":"0","summary":"3月31日,Catalyst Pharmaceuticals, Inc.公布财报,公告显示公司2024财年第一财季净利润为23.28百万美元,同比减少21.27%;其中营业收入为98.51百万美元,同比增加15.39%,每股基本收益为0.20美元。机构评级:截至2024年3月31日,当前有7家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测,其中目标均价为27.29美元,其中最低目标价为24.00美元,最高目标价为34.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051800155887750692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051800155887750692&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"2434787853","title":"HC Wainwright & Co.:维持Catalyst Pharmaceuticals(CPRX.US)评级,由买入调整至买入评级, 目标价由24.00美元调整至26.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434787853","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434787853?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:25","pubTimestamp":1715343927,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:维持Catalyst Pharmaceuticals(CPRX.US)评级,由买入调整至买入评级, 目标价由24.00美元调整至26.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102025308750c3ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102025308750c3ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"2433298094","title":"Catalyst Pharmaceuticals Inc 预计每股收益 17 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433298094","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433298094?lang=zh_cn&edition=full","pubTime":"2024-05-07 10:32","pubTimestamp":1715049122,"startTime":"0","endTime":"0","summary":" * Catalyst Pharmaceuticals Inc 将于5月8日公布截至2024年3月31日的财报,预计该公司的季度收入将有所增长。) * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 17 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元,高于其最新收盘价 14.99 美元。5月7日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2422483959","title":"Catalyst Pharmaceuticals, Inc.盘中异动 大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422483959","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2422483959?lang=zh_cn&edition=full","pubTime":"2024-03-28 00:04","pubTimestamp":1711555442,"startTime":"0","endTime":"0","summary":"北京时间2024年03月28日00时04分,Catalyst Pharmaceuticals, Inc.股票出现异动,股价快速上涨5.02%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.19%。其相关个股中,Ibio, Inc.、Moolec Science Sa C/Wts 、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 涨幅较大,Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Gamida Cell Ltd.较为活跃,换手率分别为3178.86%、1187.69%、70.06%,振幅较大的相关个股有Ibio, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Stoke Therapeutics, Inc.,振幅分别为86.96%、78.00%、58.70%。Catalyst Pharmaceuticals, Inc.公司简介:Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328000403861e1b96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240328000403861e1b96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CPRX"],"gpt_icon":0},{"id":"2416152909","title":"Catalyst Pharmaceuticals, Inc.2023财年实现净利润71.41百万美元,同比减少14.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416152909","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416152909?lang=zh_cn&edition=full","pubTime":"2024-03-04 00:24","pubTimestamp":1709483043,"startTime":"0","endTime":"0","summary":"12月31日,Catalyst Pharmaceuticals, Inc.公布财报,公告显示公司2023财年净利润为71.41百万美元,同比减少14.05%;其中营业收入为3.98亿美元,同比增加85.98%,每股基本收益为0.67美元。从资产负债表来看,Catalyst Pharmaceuticals, Inc.总负债84.03百万美元,其中短期债务369000.00美元,资产负债比为0.06,流动比率为0.03。机构评级:截至2023年12月31日,当前有5家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测,其中目标均价为27.80美元,其中最低目标价为24.00美元,最高目标价为34.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403040024088afdd7ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403040024088afdd7ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"2415528927","title":"Catalyst Pharmaceuticals, Inc.股价拉升11.61% 市值涨2.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415528927","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415528927?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:32","pubTimestamp":1709217131,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日22时32分,Catalyst Pharmaceuticals, Inc.股票出现波动,股价急速拉升11.61%。截至发稿,该股报16.25美元/股,成交量28.9682万股,换手率0.24%,振幅4.95%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.31%。其相关个股中,Enveric Biosciences, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Avidity Biosciences, Inc.涨幅较大,Enveric Biosciences, Inc.、Scisparc Ltd.、Neurobo Pharmaceuticals, Inc.较为活跃,换手率分别为1713.91%、52.53%、49.56%,振幅较大的相关个股有Enveric Biosciences, Inc.、Ys Biopharma Co Ltd C/Wts 15/03/2028 、Atara Biotherapeutics, Inc.,振幅分别为33.69%、15.55%、15.35%。Catalyst Pharmaceuticals, Inc.公司简介:Catalyst Pharmaceuticals Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922321187d23ef0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922321187d23ef0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2415547381","title":"嗡嗡声--美国股票走势-Voyager Therapeutics、GoodRx Holdings、Tenet Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2415547381","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415547381?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:20","pubTimestamp":1709216448,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月29日 - 华尔街主要股指周四将高开,因为一项关键的通胀指标符合预期,从而提高了美国联邦储备委员会在今年上半年降息的希望。美东时间9:04,道指电子盘 上涨0.22%,报39,079点。标准普尔500指数小型股 上涨0.32%,报5097.25点;纳斯达克100指数小型股 上涨0.57%,报18016.75点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FA","BK4551","PSTG","BK4198","SIX","WW","CPRX","RIOT","CC","BK4192","BIRK","VKTX","BBY","BK4528","BK4585","SNOW","LU1923623000.USD","MARA","OKTA","AMC","STER","LU1244550577.SGD","AI","LU0823414478.USD","BK4098","FIGS","BK4587","BK4561","BA","GDRX","LU2286300806.USD","VTNR","COIN","DUOL","NFE","IRWD","BK4200","BK4560","LU1951198990.SGD","OLPX","ALB","BK4138","BK4076","HRL","LU1951200564.SGD","BBWI","VYGR","BK4139","ALTM","ARQT"],"gpt_icon":0},{"id":"2415141935","title":"BUZZ-催化剂公司第四季度收入增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2415141935","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415141935?lang=zh_cn&edition=full","pubTime":"2024-02-29 19:02","pubTimestamp":1709204544,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 2月29日 - ** 制药公司Catalyst Pharmaceuticals 股价盘前上涨13%至16.48美元** 该公司第四季度收入为 1.106 亿美元,高于 (link) 分析师平均预期的 1.059 亿美元 - LSEG 数据** 公司称神经肌肉疾病药物 Firdapse 的第四季度净产品收入增长 15%,达到 6980 万美元** CPRX 预测年收入在 4.55 亿美元至 4.75 亿美元之间,中间值高于分析师平均预期的 4.632 亿美元。** 截至上次收盘,股价在过去 12 个月中下跌了 4.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","CPRX","BK4139"],"gpt_icon":0},{"id":"2414868514","title":"Catalyst Pharmaceuticals Inc 预计每股收益 27 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2414868514","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414868514?lang=zh_cn&edition=full","pubTime":"2024-02-27 05:40","pubTimestamp":1708983624,"startTime":"0","endTime":"0","summary":" * Catalyst Pharmaceuticals Inc 将于2月28日公布截至2023年12月31日的财报,预计该公司的季度收入将有所增长。 * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 27 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 25.00 美元,高于其最新收盘价 14.04 美元。2月26日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.1316},{"period":"3month","weight":0.1196},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2383},{"period":"ytd","weight":0.0077}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Catalyst Pharmaceuticals, Inc.于2006年7月在特拉华州注册成立。该公司是一家商业阶段、以患者为中心的生物制药公司,专注于为患有罕见和难以治疗的疾病的患者提供新的高质量药物的许可、开发和商业化。该公司利用协调一致的勤奋努力,寻找能够改善那些患有罕见或难以治疗的疾病的人的生活的疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.053866},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.012194},{"month":3,"riseRate":0.666667,"avgChangeRate":0.104304},{"month":4,"riseRate":0.388889,"avgChangeRate":0.036621},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.032711},{"month":6,"riseRate":0.555556,"avgChangeRate":0.04776},{"month":7,"riseRate":0.611111,"avgChangeRate":0.117596},{"month":8,"riseRate":0.647059,"avgChangeRate":0.238547},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.027434},{"month":10,"riseRate":0.411765,"avgChangeRate":-0.064826},{"month":11,"riseRate":0.529412,"avgChangeRate":0.010396},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.030132}],"exchange":"NASDAQ","name":"Catalyst Pharmaceutical Partners","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Catalyst Pharmaceutical Partners,CPRX,Catalyst Pharmaceutical Partners股票,Catalyst Pharmaceutical Partners股票老虎,Catalyst Pharmaceutical Partners股票老虎国际,Catalyst Pharmaceutical Partners行情,Catalyst Pharmaceutical Partners股票行情,Catalyst Pharmaceutical Partners股价,Catalyst Pharmaceutical Partners股市,Catalyst Pharmaceutical Partners股票价格,Catalyst Pharmaceutical Partners股票交易,Catalyst Pharmaceutical Partners股票购买,Catalyst Pharmaceutical Partners股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}